Document ID: chunk:federal_register_of_legislation:F2023C00456:schedule:3:p20
Version: federal_register_of_legislation:F2023C00456
Segment Type: schedule
Provision Reference: sch 3 (pt 20/27)
Character Range: 53871–56795

name(s) of all active ingredients in the medicine, unless there are four or more active ingredients;

       and the following information is displayed in a text size of not less than 1.5 millimetres:

           (e) where there are four or more active ingredients, the names of the active ingredients; and

       (f) the quantity or proportion of all active ingredients in the medicine; and

       (g) the name of the dosage form; and

       (h) the quantity of the medicine in the container; and

       (i) the batch number of the medicine preceded by the batch number prefix; and

       (j) the expiry date of the medicine preceded by the expiry date prefix; and

           (k) the name of the sponsor or distributor as it appears on the primary pack, or registered trademark if it readily identifies the sponsor or distributor of the medicine; and

           (l) if the medicine is contained in an ampoule - a statement of the approved route of administration for the medicine, such as 'inhalation', 'For oral use only' or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine; and

           (m) if the medicine:

              (i) is an ophthalmic preparation for multidose use - a statement to the effect that the medicine should not be used later than four weeks, or another shorter period as specified in the approved product details in relation to the medicine, after the container is first opened ; or

              (ii) consists of a solid ophthalmic medicine for preparing eye drops for multidose use - a statement to the effect that the medicine when prepared should not be used later than four weeks, or another shorter period as specified in the approved product details in relation to the medicine, after the container is first opened.

       (8) Individually wrapped medicines

       (a) Subject to paragraph (b), if:

              (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories, single doses of a powder, single doses of a liquid, or a transdermal patch; and

              (ii) each dosage unit is enclosed in an individual wrapper or blister, whether sealed or unsealed; and

              (iii) one or more dosage units are enclosed in a primary pack; and

              (iv) the label on the primary pack complies with sections 8 and 9,

           then, in relation to compliance of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed:

           (v) the name of the medicine; and

              (vi) the name(s) of all active ingredients in the medicine; and

           (vii) the quantity or proportion of all active ingredients in the medicine; and

              (viii) the batch number of the medicine preceded by the batch number prefix; and

           (ix)